Verastem

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 2010-01-01

Employees: 73

Market Cap: -

Website: http://www.verastem.com

Introduction: Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Clinical Trials

Ph 1 Study of VS-4718, a FAK Inhibitor, in Combination With Nab-paclitaxel and Gemcitabine in Advanced Cancer Subjects

Phase 1

Terminated

Conditions: Pancreatic Cancer

Interventions: Drug: Part A- VS-4718, nab-paclitaxel, gemcitabine
Drug: Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine
Drug: Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine

First Posted Date: 2016-01-11

Last Posted Date: 2017-07-27

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 13

Registration Number: NCT02651727

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Gettysburg Cancer Center, Gettysburg, Pennsylvania, United States

A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma

Phase 1

Terminated

Conditions: Relapsed Malignant Mesothelioma

Interventions: Drug: VS-5584 and VS-6063

First Posted Date: 2015-02-26

Last Posted Date: 2017-01-30

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 21

Registration Number: NCT02372227

Locations: 🇬🇧
University of Leicester, Leicester, United Kingdom
🇺🇸
Memorial Sloane Kettering Cancer Center, New York, New York, United States
🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States

and more 1 locations

Dose Escalation Study in Acute Myeloid or B-Cell Acute Lymphoblastic Leukemia

Phase 1

Withdrawn

Conditions: Relapsed or Refractory Acute Myeloid Leukemia
Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia

Interventions: Drug: VS-4718

First Posted Date: 2014-08-13

Last Posted Date: 2017-01-27

Lead Sponsor: Verastem, Inc.

Registration Number: NCT02215629

Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants

Phase 2

Terminated

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: VS-6063

First Posted Date: 2013-12-06

Last Posted Date: 2024-02-20

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 35

Registration Number: NCT02004028

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Phase I Dose Escalation Study of VS-5584 in Subjects With Advanced Non-Hematologic Malignancies or Lymphoma

Phase 1

Terminated

Conditions: Non Hematologic Cancers
Metastatic Cancer
Lymphoma

Interventions: Drug: VS-5584

First Posted Date: 2013-11-25

Last Posted Date: 2017-01-27

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 75

Registration Number: NCT01991938

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States

and more 2 locations

Phase II Study of VS-6063 in Patients With KRAS Mutant Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer
Lung Cancer

Interventions: Drug: defactinib (VS-6063)

First Posted Date: 2013-09-27

Last Posted Date: 2017-04-13

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 55

Registration Number: NCT01951690

Locations: 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸
University of Colorado Cancer Center, Anschutz Medical Campus, Denver, Colorado, United States

and more 6 locations

Phase I Dose Escalation Study of VS-6063 in Japanese Subjects With Non-Hematologic Malignancies

Phase 1

Completed

Conditions: Non Hematologic Cancers

Interventions: Drug: Defactinib

First Posted Date: 2013-09-16

Last Posted Date: 2017-03-09

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 9

Registration Number: NCT01943292

Locations: 🇯🇵
Kinki University Hospital, Osaka, Japan

Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma

Phase 2

Terminated

Conditions: Malignant Pleural Mesothelioma

Interventions: Drug: Placebo
Drug: defactinib (VS-6063)

First Posted Date: 2013-06-06

Last Posted Date: 2017-01-30

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 344

Registration Number: NCT01870609

Locations: 🇺🇸
University of California San Francisco Medical Center, San Francisco, California, United States
🇫🇷
Gustave Roussy, Villejuif, France
🇬🇧
Royal Surrey County Hospital, Guildford, United Kingdom

and more 70 locations

Phase I Dose Escalation Study of VS-4718 in Subjects With Metastatic Non-Hematologic Malignancies

Phase 1

Terminated

Conditions: Non Hematologic Cancers
Metastatic Cancer

Interventions: Drug: VS-4718

First Posted Date: 2013-05-08

Last Posted Date: 2017-07-28

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 48

Registration Number: NCT01849744

Locations: 🇺🇸
Washington University School of Medicine, Division of Oncology, Saint Louis, Missouri, United States
🇺🇸
HonorHealth Research Institute, Scottsdale, Arizona, United States
🇺🇸
Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, California, United States

and more 2 locations

Phase I/Ib Study of Paclitaxel in Combination With VS-6063 in Patients With Advanced Ovarian Cancer

Phase 1

Completed

Conditions: Ovarian Cancer

Interventions: Drug: defactinib
Drug: Paclitaxel

First Posted Date: 2013-01-29

Last Posted Date: 2017-05-17

Lead Sponsor: Verastem, Inc.

Target Recruit Count: 22

Registration Number: NCT01778803

Locations: 🇺🇸
Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy